BELLE PRO SKIN SCAN TEST RESULTS

The Belle Pro AI Skin Scan technology has consistently surpassed traditional clinical diagnoses in every test, leading to its formal recognition by the World Health Organization for its clinical accuracy and reliability.

Belle AI 1K Validation Study

Validated from 2014 untrained clinical images addressed by BelleAI for comparison to 400 possible dermatological conditions.


Results show that BelleAI results are among the top 5 comparative references 92.2% of the time.

Belle Pro AI Skin Scan Validation Results
Belle AI Dermoscopy Trial with University of Trieste

Another study was conducted at the University of Trieste in Italy. A blind test of 4,926 images independently scored by Fraunhofer Heinrich-Hertz Institute (Berlin).

Dermoscopy Trial Image 1
Belle Pro AI Skin Scan Validation Results
BelleAI’s Superior Performance on Dark Skin Lesions

Source: Groh, M. et al., “Deep learning-aided decision support for diagnosis of skin disease across skin tones”, Nature Medicine. February 4, 2024.

Dark Skin Lesion Study Image 1
Dark Skin Lesion Study Image 2
Press Release - CMS Selected Belle.ai to Present its AI for Dermatology in the First Artificial Intelligence Demo Day

Attended by over 800 U.S. Department of Health and Human Services Personnel

CAMBRIDGE, Nov. 12, 2024—The Centers for Medicare & Medicaid Services (CMS) selected Belle.ai as one of six inaugural participants in the first quarterly CMS Artificial Intelligence Demo Day, held Nov. 7 at CMS’s headquarters in Baltimore.


“Out of a pool of 300 applicants, your health-related AI products and services stood out as exceptional, earning you this opportunity to showcase your innovations,” CMS said when informing Belle.ai of its selection.


In their presentation, a team from Belle.ai demonstrated the company’s smartphone-based skin AI app for healthcare professionals, called BellePro™. From a smartphone photo, BellePro uses geometric analyses to find comparable references for more than 1,600 skin conditions. Belle.ai’s technology also proposes objective severity scoring for immune-mediated skin disorders (including psoriasis, eczema, alopecia areata and vitiligo) for patients already diagnosed with these conditions, to help healthcare professionals track progression over time. Belle.ai’s software is used by primary care providers, dermatologists, local and public health agencies, and life sciences companies.


CMS set up its quarterly Demo Days “to highlight the diverse range of AI applications in clinical, research, administrative, and other healthcare settings,” CMS said. The agency issued an RFI in September to gather information “about existing AI technologies supporting health care outcomes and service delivery which are relevant to CMS programs and operations.” CMS provides health coverage to more than 160 million people through Medicare, Medicaid, the Children's Health Insurance Program, and the Health Insurance Marketplace. CMS works in partnership with the health care community under these programs to improve quality, equity, and outcomes in the U.S. health care system.